Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Rivaroxaban 8Surveys and Questionnaires 7Heparin, Low-Molecular-Weight 5apixaban 4fludarabine 3Blood Specimen Collection 3pegfilgrastim 2epoetin beta 2Therapeutics 2Polymerase Chain Reaction 2Piperacillin, Tazobactam Drug Combination 2Observation 2Microarray Analysis 2Melphalan 2Influenza Vaccines 2Immunoenzyme Techniques 2Flow Cytometry 2Epoetin Alfa 2Data Collection 2Dabigatran 2Biopsy 2ziprasidone 1ribociclib 1ravulizumab 1palbociclib 1oprelvekin 1iron isomaltoside 1000 1fludarabine phosphate 1edoxaban 1calcium heparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Glycopeptides × Classical hematology × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡